A Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation Phase 1b Study to Evaluate the Safety and Immunogenicity of an Intranasal Live Attenuated Respiratory Syncytial Virus (RSV) Vaccine in Seropositive Young Children
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Meissa Vaccines, Inc.
- Enrollment
- 34
- Locations
- 3
- Primary Endpoint
- Unsolicited AEs
Study Overview
Brief Summary
This study evaluates an investigational vaccine that is designed to protect humans against infection with respiratory syncytial virus (RSV) and is administered as drops in the nose. Specifically, the study analyzes the safety of, and the immune response to, the vaccine when administered to healthy children between the ages of 15 and 59 months who are seropositive to RSV.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Sequential
- Primary Purpose
- Prevention
- Masking
- Single (Participant)
Masking Description
The study is single-mask in 2 of the 3 dosage groups: study participants and their parent(s)/guardian(s) will not know their child's study assignment, whereas investigators, site staff, and site pharmacists will remain unmasked.
Eligibility Criteria
- Ages
- 15 Months to 59 Months (Child)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Children aged 15-59 months
- •Good health based on history, physical examination and medical record review, without evidence or suspicion of chronic disease
- •Seropositive to RSV, as defined by serum neutralizing antibody titer above the threshold described in the study Analytical Plan
- •Written informed consent provided by parent(s)/guardian(s)
Exclusion Criteria
- •Known or suspected chronic illness, particularly cardiopulmonary (including asthma or reactive airways disease), metabolic, hepatic, renal, or infectious (including recurrent or chronic sinusitis)
- •Known or suspected immunodeficiency
- •Household or close contact with anyone ≤ 6 months of age or with immunocompromised individual(s)
- •Nasal obstruction (including due to anatomic/structural causes, acute or chronic rhinosinusitis, or other causes)
- •Receipt of immunoglobulins, monoclonal antibodies and/or any blood products, or ribavirin within 3 months prior to study inoculation, or planned during study period
- •Receipt of an investigational RSV vaccine at any time
- •Any other condition that, in the judgment of the investigator, would be a risk to participant's safety and/or may interfere with study procedures or interpretation of results
Arms & Interventions
Dosage Group 1: RSV Vaccine Dosage 1
Participants in this arm will receive a single intranasal dose of the investigational RSV vaccine at Dosage 1.
Intervention: Investigational RSV vaccine MV-012-968 (Dosage 1) (Biological)
Dosage Group 1: Placebo
Participants in this arm will receive a single intranasal dose of placebo.
Intervention: Placebo (Other)
Dosage Group 2: RSV Vaccine Dosage 2
Participants in this arm will receive a single intranasal dose of the investigational RSV vaccine at Dosage 2.
Intervention: Investigational RSV vaccine MV-012-968 (Dosage 2) (Biological)
Dosage Group 2: Placebo
Participants in this arm will receive a single intranasal dose of placebo.
Intervention: Placebo (Other)
Dosage Group 3: RSV Vaccine Dosage 3
Participants in this arm will receive a single intranasal dose of the investigational RSV vaccine at Dosage 3.
Intervention: Investigational RSV vaccine MV-012-968 (Dosage 3) (Biological)
Outcomes
Primary Outcomes
Unsolicited AEs
Time Frame: Immediate post-vaccination period
Frequency of unsolicited AEs will be measured, categorized by severity. Unsolicited AEs are any untoward medical occurrences in a participant administered the investigational vaccine, regardless of causal relationship to the investigational vaccine. Unsolicited AEs can include unfavorable and unintended signs (including abnormal laboratory findings), symptoms, or diseases temporally associated with the use of the investigational vaccine.
Solicited adverse events (AEs)
Time Frame: Immediate post-vaccination period
Frequency of solicited AEs will be measured, categorized by severity. Solicited AEs are predefined AEs that may occur after investigational vaccine administration
Serious adverse events (SAEs)
Time Frame: Full study duration, an average of 6 months
Frequency of SAEs will be measured, categorized by vaccine-relatedness. SAEs are AEs, whether considered causally related to the investigational vaccine or not, that threaten life or result in any of the following: death, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or congenital anomaly/birth defect.
Medically attended adverse events (MAEs)
Time Frame: Full study duration, an average of 6 months
Frequency of MAEs will be measured, categorized by vaccine-relatedness. MAEs are AEs, whether considered causally related to the investigational vaccine or not, with unscheduled medically attended visits, such as urgent care visits, acute primary care visits, emergency department visits, or other previously unplanned visits to a medical provider. Scheduled medical visits such as routine physicals, wellness checks, 'check-ups', and vaccinations, are not considered MAEs.
Secondary Outcomes
- Potential vaccine virus shedding: frequency(Baseline through Day 28, an average of four (4) weeks)
- Potential vaccine virus shedding: magnitude(Baseline through Day 28, an average of four (4) weeks)
- Change in serum RSV-specific neutralizing antibody titers(Baseline through Day 28, an average of six (6) weeks)
- Change in serum binding (RSV F-specific) antibody titers(Baseline through Day 28, an average of six (6) weeks)
- Change in nasal mucosal binding (RSV F-specific) antibody titers(Baseline through Day 28, an average of six (6) weeks)
- Potential vaccine virus shedding: duration(Baseline through Day 28, an average of four (4) weeks)